drugset / Trial / NCT05944237
HTL0039732 in Participants With Advanced Solid Tumours
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.
Timeline
- Start
- 2023-07-13
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | HTL0039732 | Small molecule | — | Oral |